Lichen Planus Treatment Market to Derive Enormous Growth from the Expected launch of Emerging Therapies in the Forecast Period (2020-30)

Lichen Planus Treatment Market to Derive Enormous Growth from the Expected launch of Emerging Therapies in the Forecast Period (2020-30)

Lichen Planus Market
The total Lichen Planus market size will include both the market size of upcoming therapies like Rivelin-clobetasoL, Valchlor (mechlorethamine), KPL-716, and others, as well as the market size of current Lichen Planus treatment regimens in the 7MM.

DelveInsight’s Lichen Planus market report provides an in-depth understanding of the Lichen Planus, historical and forecasted epidemiology, as well as Lichen Planus market trends in the 7MM (the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). The report also examines current Lichen Planus treatment practices/algorithms, Lichen Planus market drivers, Lichen Planus market barriers, and unmet medical needs to identify and evaluate the market’s underlying potential.

Key Highlights from the Lichen Planus Market Report

  • According to the National Organization for Rare Disorders (NORD), Lichen Planus affects less than 1% of the global population.

  • According to the Human Phenotype Ontology (HPO) Database, baldness, hyperkeratosis, lichenification, and papule occur in 80-99 percent of Lichen Planus patients, while aberrant fingernail morphology occurs in 30-79 percent.

  • Several key pharmaceutical companies such as AFYX Therapeutics, Novartis, Actellion, Kiniksa Pharmaceuticals, and others are developing novel therapies to boost the Lichen Planus treatment outlook.

  • Novartis is developing AIN457 (Cosentyx), a IL17A (Anti-interleukin-17 monoclonal antibody) inhibitor. The drug is currently in phase II clinical development for the treatment of Lichen Planus.

  • Some of the other promising therapies which are in the pipeline for Lichen Planus treatment include Rivelin-clobetasoL (AFYX Therapeutics), Valchlor (mechlorethamine) (Actellion), and KPL-716 (Kiniksa Pharmaceuticals). 

What to know more? Request for sample @ Lichen Planus Oral Treatment

The Lichen Planus market report covers current treatment practices, emerging drugs, individual therapies’,  Lichen Planus market share, and current and forecasted Lichen Planus market size from 2017 to 2030, segmented by seven major markets.

Lichen Planus: Overview

Lichen Planus is a chronic, immune-mediated mucocutaneous disease that can affect mucosal surfaces, particularly those that line the mouth. It can affect the skin (cutaneous lichen planus), the mouth (oral lichen planus), the genitalia (penile or vulvar lichen planus), the scalp (lichen planopilaris), the nails, or the esophagus. Reticular, atrophic/erosive, and plaque-like oral Lichen Planus are some of the different types of oral Lichen Planus that can arise alone or in combination.

Lichen Planus Epidemiology Segmentation

The Lichen Planus report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

  • Lichen Planus Total Prevalent Population 

  • Lichen Planus Type-SPecific Prevalent Population

  • Lichen Planus Gender-Specific Prevalent Population

  • Lichen Planus Diagnosed and Treatable Cases

Lichen Planus Treatment Landscape

There is no cure for Lichen Planus and the current therapeutic market is mostly based on symptom relief and scar reduction from erosive lesions. The current treatment for Lichen Planus includes Antihistamines, Topical and Oral Corticosteroids, and Light therapy.

Get complete information on lichen planus treatment guidelines @ Lichen Planus Management

Lichen Planus Market

The total Lichen Planus market size will comprise both the market size of forthcoming therapies such as  Rivelin-clobetasoL, Valchlor (mechlorethamine), KPL-716, and others and the market size of current Lichen Planus treatment regimens in the 7MM.

Lichen Planus Emerging Drugs and Major Companies 

  • Rivelin-clobetasoL: AFYX Therapeutics

  • AIN457 (Cosentyx): Novartis

  • Valchlor (mechlorethamine): Actellion

  • KPL-716: Kiniksa Pharmaceuticals

Table of Contents 

1.

Report Introduction

2.

Lichen Planus: Market Overview at a Glance

3.

Disease Background and Overview: Lichen Planus 

4.

Lichen Planus Epidemiology and Patient Population

5.

Lichen Planus: Country-Wise Epidemiology

6.

Lichen Planus Treatments & Medical Practices

7.

Lichen Planus Emerging Therapies

8.

Lichen Planus: Market Size

9.

Lichen Planus7MM: Country-Wise Market Analysis

10.

Lichen Planus Market Drivers

11.

Lichen Planus Market Barriers

12.

Report Methodology

13.

DelveInsight Capabilities

14.

Disclaimer

15.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Oral Mucositis Market 

Get comprehensive historical and forecast analysis of Oral Mucositis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Access Pharmaceuticals, Camurus, Innovation Pharmaceuticals, BrainCool, NeoMedLight, Soligenix, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/


Posted

in

by

Tags: